Introduction: We retrospectively assessed prognostic value of circulating cell-free DNA
(cfDNA) using data from the phase III ALEX study in treatment-naïve, advanced ALK+ …

Purpose: Central nervous system metastases are a prominent cause of morbidity and
mortality in patients with ALK-positive (ALK+) non–small cell lung cancer (NSCLC). The …

Targeted therapy has stepped into the perioperative treatment arena and launched a radical
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …

Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the
first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients …

Background Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have
significantly improved the clinical outcomes of patients with ALK-positive non-small cell lung …

Background The prognosis of patients with NSCLC harboring oncogenic driver gene
alterations, such as EGFR gene mutations or ALK fusion, has improved dramatically with the …

Simple Summary Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
(NSCLC) was first reported in 2007. Following the development of crizotinib as a tyrosine …

Over the past 2 decades, rapid advances in molecular profiling and the development of
targeted therapies have dramatically improved the clinical course of advanced non-small …

Lung cancer is one of the deadliest cancers globally and accounts for most of the cancer-
related deaths in India. Comprehensive data on lung cancer in India are lacking. This review …

Abstract Background DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer
patients represent promising biomarkers for minimally invasive tumor detection. The high …